乳腺癌新辅助治疗个体化管理

近年来乳腺癌新辅助治疗作为标准治疗手段之一愈发受到关注，与辅助治疗相比是否有优势存在的争论也颇多。然而经新辅助化疗达到病理完全缓解（PCR）可以显著改善预后这个不争的事实展示了该治疗方式的美好前景，同时也促使外科医生思考哪类病人能够达到PCR，哪些方案能够使病人从新辅助化疗中最大获益。另外，在治疗过程中运用MRI、循环肿瘤细胞测定等手段对疾病进行监测和疗效预测，使乳腺癌新辅助治疗在安全、可控中进行，做到真正的个体化治疗。

The individualized management for neoadjuvant therapy of breast cancer

As one of the standardized treatments, neoadjuvant treatment for breast cancer has been paid more and more attention. At the same time, discussion on the advantage and shortage of neoadjuvant treatment compared with adjuvant treatment exists constantly. However, the fact that the patients who achieved pCR from neoadjuvant treatment had a much better prognosis reveals a promising perspective. It also urges surgeons to study on the available biomarker to predict pCR and the most effective schedule to achieve ...